188 related articles for article (PubMed ID: 27379943)
1. Highlights in breast cancer from the 2016 American Society of Clinical Oncology Annual Meeting.
Rugo HS
Clin Adv Hematol Oncol; 2016 Jul; 14(7):494-7. PubMed ID: 27379943
[No Abstract] [Full Text] [Related]
2. Trial Validates Biosimilar for Trastuzumab.
Cancer Discov; 2016 Jul; 6(7):686-7. PubMed ID: 27277256
[TBL] [Abstract][Full Text] [Related]
3. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
Kim WS; Coiffier B; Kwon HC; Kim S
Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
[TBL] [Abstract][Full Text] [Related]
4. Highlights in kidney cancer from the 2016 American Society of Clinical Oncology Annual Meeting.
Clin Adv Hematol Oncol; 2016 Aug; 14(8):594-6. PubMed ID: 27487102
[No Abstract] [Full Text] [Related]
5. What is optimal first-line treatment of unresectable or advanced BRAF-mutant melanoma?
Atkins MB
Clin Adv Hematol Oncol; 2016 Jun; 14(6):417-9. PubMed ID: 27379810
[No Abstract] [Full Text] [Related]
6. Sequencing of Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer.
Brose MS
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 9):7-12. PubMed ID: 27168342
[No Abstract] [Full Text] [Related]
7. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
[TBL] [Abstract][Full Text] [Related]
8. Milestones over the development of SB3, a trastuzumab biosimilar.
Pivot X; Bondarenko I; Petit T; Curtit E
Future Oncol; 2018 Nov; 14(27):2795-2803. PubMed ID: 29927335
[TBL] [Abstract][Full Text] [Related]
9. Highlights of the American Society of Clinical Oncology annual meeting 2005. 13-17 May, 2005, Florida, USA.
Burstein HJ
Expert Rev Anticancer Ther; 2005 Aug; 5(4):581-3. PubMed ID: 16111459
[No Abstract] [Full Text] [Related]
10. Trastuzumab biosimilar shows potential for breast cancer.
Baker H
Lancet Oncol; 2017 Jan; 18(1):e4. PubMed ID: 27956154
[No Abstract] [Full Text] [Related]
11. Highlights in Metastatic Prostate Cancer From the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: Commentary.
Shore ND
Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):17-9. PubMed ID: 27167847
[No Abstract] [Full Text] [Related]
12. Biosimilar Treatments Have Practice Implications.
Wiley K
ONS Connect; 2016 Apr; 31(4):38. PubMed ID: 27209660
[No Abstract] [Full Text] [Related]
13. Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
López-Tarruella S; Jerez Y; Márquez-Rodas I; Echavarria I; Martin M
Future Oncol; 2017 Oct; 13(24):2137-2149. PubMed ID: 28758424
[TBL] [Abstract][Full Text] [Related]
14. Anti-epidermal growth factor receptor strategies for advanced breast cancer.
Campos SM
Cancer Invest; 2008 Oct; 26(8):757-68. PubMed ID: 18853311
[No Abstract] [Full Text] [Related]
15. American Society of Clinical Oncology--40th Annual Meeting. Selected highlights. 5-8 June 2004, New Orleans, LA, USA.
Erlich R; Harrison R
IDrugs; 2004 Jul; 7(7):621-4. PubMed ID: 15243857
[No Abstract] [Full Text] [Related]
16. The American Society of Clinical Oncology 2009 Breast Cancer Symposium, San Francisco, CA, October 8-10, 2009.
Quill T; Abair T; Garcia K
Clin Breast Cancer; 2009 Nov; 9(4):213-8. PubMed ID: 19933075
[No Abstract] [Full Text] [Related]
17. The role of sorafenib in hepatocellular carcinoma.
Gholam P
Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
[No Abstract] [Full Text] [Related]
18. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
19. Progress in breast cancer-can we do better?
Dent SF
Curr Oncol; 2018 Jun; 25(Suppl 1):S7-S8. PubMed ID: 29910642
[No Abstract] [Full Text] [Related]
20. Meeting highlights 38th annual meeting of the American Society of Clinical Oncology. Advances in adjuvant chemotherapy for management of breast cancer: the emerging role of docetaxel.
Street JC; Taguchi T
Gan To Kagaku Ryoho; 2002 Sep; 29(9):1689-92. PubMed ID: 12355960
[No Abstract] [Full Text] [Related]
[Next] [New Search]
